Research Initiative

 
Stock Quotes for Research Initiative top ^
  • Industry: Business Services
  • Sector: Industrials
  • Stock Style: Mid Value
Sign-up for rtoky investment picks
  • Industry: Communication Equipment
  • Sector: Technology
  • Stock Style: Mid Growth
Sign-up for iiji investment picks
  • Industry: Oil & Gas Equipment & Services
  • Sector: Energy
  • Stock Type: Distressed
Sign-up for usei investment picks
  • Industry: Solar
  • Sector: Technology
  • Stock Type: Distressed
Sign-up for sopv investment picks
  • Industry: Solar
  • Sector: Technology
  • Stock Type: Distressed
Sign-up for snry investment picks
  • Industry: Communication Equipment
  • Sector: Technology
  • Stock Style: Mid Growth
Sign-up for 3774 investment picks
  • Industry: Internet Content & Information
  • Sector: Technology
  • Stock Style: Small Growth
Sign-up for 3658 investment picks

 
News Articles for Research Initiative top ^
Company Announces First Quarter Earnings Reporting Date COLUMBUS, Ohio , May 12, 2014 /PRNewswire/ -- DSW Inc. (NYSE: DSW) , a leading branded footwear and accessories retailer, announced the closing of its initial acquisition of Town Shoes Limited, the largest footwear and accessories retailer in Canada , for CAD$75.5 million ( USD$68.7 million ) in cash.
Sign-up for DSW Inc. Completes Acquisition of Initial Interest in Town Shoes investment picks
SAN FRANCISCO (MarketWatch) - Kyle Bass's Hayman fund initiated a stake in Herbalife (HLF) and sold off its 7 million shares of Kinder Morgan (KMI) during the first quarter, according to a filing Thursday with the Securities and Exchange Commission.
Sign-up for Kyle Bass's Hayman fund initiates Herbalife, Verizon stakes, dumps Kinder: 13F investment picks
- Dosing Initiated in Phase 1 Study to Evaluate the Safety, Tolerability and Antiviral Activity of ACH-3422, NS5B Uridine-Analog Nucleotide Prodrug - NEW HAVEN, Conn., April 30, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that is has begun dosing study participants with ACH-3422, Achillion's proprietary uridine-analog nucleotide inhibitor, in a Phase 1 clinical trial.
Sign-up for Achillion Advances ACH-3422, Uridine-Analog Nucleotide Inhibitor, Into Clinical Trial; Initiates Phase 2 Pilot Study With ACH-3102, NS5A Inhibitor, for HCV investment picks
NATICK, Mass., April 24, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) , a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the initiation of a Phase 2 trial of its novel, oral Selective Inhibitor of Nuclear Export (SINE) compound Selinexor (KPT-330) in patients with advanced gynecologic malignancies including cervical, ovarian and uterine carcinomas.
Sign-up for Phase 2 Study of Selinexor (KPT-330) Initiated by Karyopharm in Patients With Advanced Gynecologic Malignancies (SIGN Study) investment picks
NATICK, Mass., April 29, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) , a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the initiation of a Phase 2 trial of its novel, oral Selective Inhibitor of Nuclear Export (SINE) compound Selinexor (KPT-330) in patients with glioblastoma following treatment with radiation and temozolomide.
Sign-up for Phase 2 Study of Selinexor (KPT-330) Initiated by Karyopharm in Patients With Recurrent Glioblastoma After Failure of Radiation and Temozolomide (KING Study) investment picks
VANCOUVER, Wash., May 1, 2014 (GLOBE NEWSWIRE) -- Papa Murphy's Holdings, Inc. ("Papa Murphy's") (Nasdaq:FRSH) today announced the pricing of its initial public offering of 5,833,333 shares of common stock at a price to the public of $11.00 per share.
Sign-up for Papa Murphy's Holdings, Inc. Prices Its Initial Public Offering investment picks
NEW YORK, May 9, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) , a research and development company with a primary focus in ophthalmology, today announced the initiation of a Phase II investigator sponsored clinical trial, OHR-005, testing Squalamine Eye Drops in patients with diabetic macular edema (DME). "Diabetic eye disease is a major healthcare problem with over half a million patients in the US suffering from macular edema," said Dr.
Sign-up for Ohr Pharmaceutical Announces Initiation of Investigator Sponsored Trial of Squalamine Eye Drops in Diabetic Macular Edema investment picks
NANJING, China, May 9, 2014 (GLOBE NEWSWIRE) -- Tuniu Corporation (Nasdaq:TOUR) ("Tuniu" or the "Company"), a leading online leisure travel company in China, today announced that it has priced its initial public offering of 8,000,000 American Depositary Shares ("ADSs"), each representing three Class A ordinary shares of the Company, at US$9.00 per ADS for a total offering size of approximately US$72.0 million, assuming the underwriters do not exercise their option to purchase additional ADSs.
Sign-up for Tuniu Corporation Announces Pricing of Initial Public Offering investment picks
BURLINGTON, Mass., May 7, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced the closing of its previously announced initial public offering of 1,500,000 shares of its common stock at a price to the public of $8.00 per share.
Sign-up for Aldeyra Therapeutics Announces Closing of Initial Public Offering of 1,500,000 Shares of Common Stock investment picks
PRINCETON, N.J., May 5, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS) , a biotechnology company developing cancer immunotherapies, announced it intends to initiate a clinical development program with its product candidate, ADXS-cHER2, for the treatment of pediatric osteosarcoma.
Sign-up for Advaxis to Initiate Clinical Development of ADXS-cHER2 Immunotherapy to Treat Pediatric Bone Cancer investment picks
SAN DIEGO, May 12, 2014 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) , a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the initiation of a Phase 2b clinical trial of its lead drug candidate, emricasan, in post-orthotopic liver transplant (POLT) recipients with reestablished liver fibrosis post-transplant as a result of recurrent hepatitis C virus (HCV) infection who have successfully achieved a sustained viral response (SVR) following HCV antiviral therapy (POLT-HCV-SVR). The placebo-controlled, double-blind (open to sponsor) trial is designed to enroll approximately 60 patients at approximately 15 planned U.S. clinical sites.
Sign-up for Conatus Pharmaceuticals Initiates Phase 2b Trial Targeting Fibrosis in Liver Transplant Recipients investment picks
BEIJING , May 16, 2014 /PRNewswire/ -- Jumei International Holding Limited (NYSE: JMEI) ("Jumei" or the "Company"), China's leading online retailer of beauty products, today announced that it has priced its initial public offering of 11,140,000 American depositary shares ("ADSs") by the Company at US$22 .00 per ADS for a total offering size of approximately US$245.1 million , assuming the underwriters do not exercise their option to purchase additional ADSs.
Sign-up for Jumei Announces Pricing of Initial Public Offering investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Research Initiative
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Research Infrastructure  |  Next: Research Institutes